Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Weidenbusch, Marc (44961542100)"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Exome Sequencing and Identification of Phenocopies in Patients With Clinically Presumed Hereditary Nephropathies
    (2020)
    Riedhammer, Korbinian M. (57200625458)
    ;
    Braunisch, Matthias C. (57192699344)
    ;
    Günthner, Roman (6507490502)
    ;
    Wagner, Matias (35370135300)
    ;
    Hemmer, Clara (57216548595)
    ;
    Strom, Tim M. (7102342124)
    ;
    Schmaderer, Christoph (16204132800)
    ;
    Renders, Lutz (6602849386)
    ;
    Tasic, Velibor (7003911066)
    ;
    Gucev, Zoran (15765372600)
    ;
    Nushi-Stavileci, Valbona (57193881397)
    ;
    Putnik, Jovana (14008113300)
    ;
    Stajić, Nataša (6602606131)
    ;
    Weidenbusch, Marc (44961542100)
    ;
    Uetz, Barbara (57199583178)
    ;
    Montoya, Carmen (7005889581)
    ;
    Strotmann, Peter (56286928800)
    ;
    Ponsel, Sabine (56986500900)
    ;
    Lange-Sperandio, Baerbel (6506453628)
    ;
    Hoefele, Julia (57196082805)
    Rationale & Objective: Hereditary nephropathies are clinically and genetically heterogeneous disorders. For some patients, the clinical phenotype corresponds to a specific hereditary disease but genetic testing reveals that the expected genotype is not present (phenocopy). The aim of this study was to evaluate the spectrum and frequency of phenocopies identified by using exome sequencing in a cohort of patients who were clinically suspected to have hereditary kidney disorders. Study Design: Cross-sectional cohort study. Setting & Participants: 174 unrelated patients were recruited for exome sequencing and categorized into 7 disease groups according to their clinical presentation. They included autosomal dominant tubulointerstitial kidney disease, Alport syndrome, congenital anomalies of the kidney and urinary tract, ciliopathy, focal segmental glomerulosclerosis/steroid-resistant nephrotic syndrome, VACTERL association, and “other.” Results: A genetic diagnosis (either likely pathogenic or pathogenic variant according to the guidelines of the American College of Medical Genetics) was established using exome sequencing in 52 of 174 (30%) cases. A phenocopy was identified for 10 of the 52 exome sequencing–solved cases (19%), representing 6% of the total cohort. The most frequent phenocopies (n = 5) were associated with genetic Alport syndrome presenting clinically as focal segmental glomerulosclerosis/steroid-resistant nephrotic syndrome. Strictly targeted gene panels (<25 kilobases) did not identify any of the phenocopy cases. Limitations: The spectrum of described phenocopies is small. Selection bias may have altered the diagnostic yield within disease groups in our study population. The study cohort was predominantly of non-Finnish European descent, limiting generalizability. Certain hereditary kidney diseases cannot be diagnosed by using exome sequencing (eg, MUC1-autosomal dominant tubulointerstitial kidney disease). Conclusions: Phenocopies led to the recategorization of disease and altered clinical management. This study highlights that exome sequencing can detect otherwise occult genetic heterogeneity of kidney diseases. © 2020 National Kidney Foundation, Inc.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Is there a dominant-negative effect in individuals with heterozygous disease-causing variants in COL4A3/COL4A4?
    (2024)
    Riedhammer, Korbinian M. (57200625458)
    ;
    Simmendinger, Hannes (57897933000)
    ;
    Tasic, Velibor (7003911066)
    ;
    Putnik, Jovana (14008113300)
    ;
    Abazi-Emini, Nora (57896737400)
    ;
    Stajic, Natasa (6602606131)
    ;
    Berutti, Riccardo (24483074500)
    ;
    Weidenbusch, Marc (44961542100)
    ;
    Patzer, Ludwig (6601983901)
    ;
    Lungu, Adrian (35812503300)
    ;
    Milosevski-Lomic, Gordana (20436011000)
    ;
    Günthner, Roman (6507490502)
    ;
    Braunisch, Matthias C. (57192699344)
    ;
    Ćomić, Jasmina (57896737200)
    ;
    Hoefele, Julia (57196082805)
    Alport syndrome (AS) shows a broad phenotypic spectrum ranging from isolated microscopic hematuria (MH) to end-stage kidney disease (ESKD). Monoallelic disease-causing variants in COL4A3/COL4A4 have been associated with autosomal dominant AS (ADAS) and biallelic variants with autosomal recessive AS (ARAS). The aim of this study was to analyze clinical and genetic data regarding a possible genotype–phenotype correlation in individuals with disease-causing variants in COL4A3/COL4A4. Eighty-nine individuals carrying at least one COL4A3/COL4A4 variant classified as (likely) pathogenic according to the American College of Medical Genetics guidelines and current amendments were recruited. Clinical data concerning the prevalence and age of first reported manifestation of MH, proteinuria, ESKD, and extrarenal manifestations were collected. Individuals with monoallelic non-truncating variants reported a significantly higher prevalence and earlier diagnosis of MH and proteinuria than individuals with monoallelic truncating variants. Individuals with biallelic variants were more severely affected than those with monoallelic variants. Those with biallelic truncating variants were more severely affected than those with compound heterozygous non-truncating/truncating variants or individuals with biallelic non-truncating variants. In this study an association of heterozygous non-truncating COL4A3/COL4A4 variants with a more severe phenotype in comparison to truncating variants could be shown indicating a potential dominant-negative effect as an explanation for this observation. The results for individuals with ARAS support the, still scarce, data in the literature. © 2024 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Is there a dominant-negative effect in individuals with heterozygous disease-causing variants in COL4A3/COL4A4?
    (2024)
    Riedhammer, Korbinian M. (57200625458)
    ;
    Simmendinger, Hannes (57897933000)
    ;
    Tasic, Velibor (7003911066)
    ;
    Putnik, Jovana (14008113300)
    ;
    Abazi-Emini, Nora (57896737400)
    ;
    Stajic, Natasa (6602606131)
    ;
    Berutti, Riccardo (24483074500)
    ;
    Weidenbusch, Marc (44961542100)
    ;
    Patzer, Ludwig (6601983901)
    ;
    Lungu, Adrian (35812503300)
    ;
    Milosevski-Lomic, Gordana (20436011000)
    ;
    Günthner, Roman (6507490502)
    ;
    Braunisch, Matthias C. (57192699344)
    ;
    Ćomić, Jasmina (57896737200)
    ;
    Hoefele, Julia (57196082805)
    Alport syndrome (AS) shows a broad phenotypic spectrum ranging from isolated microscopic hematuria (MH) to end-stage kidney disease (ESKD). Monoallelic disease-causing variants in COL4A3/COL4A4 have been associated with autosomal dominant AS (ADAS) and biallelic variants with autosomal recessive AS (ARAS). The aim of this study was to analyze clinical and genetic data regarding a possible genotype–phenotype correlation in individuals with disease-causing variants in COL4A3/COL4A4. Eighty-nine individuals carrying at least one COL4A3/COL4A4 variant classified as (likely) pathogenic according to the American College of Medical Genetics guidelines and current amendments were recruited. Clinical data concerning the prevalence and age of first reported manifestation of MH, proteinuria, ESKD, and extrarenal manifestations were collected. Individuals with monoallelic non-truncating variants reported a significantly higher prevalence and earlier diagnosis of MH and proteinuria than individuals with monoallelic truncating variants. Individuals with biallelic variants were more severely affected than those with monoallelic variants. Those with biallelic truncating variants were more severely affected than those with compound heterozygous non-truncating/truncating variants or individuals with biallelic non-truncating variants. In this study an association of heterozygous non-truncating COL4A3/COL4A4 variants with a more severe phenotype in comparison to truncating variants could be shown indicating a potential dominant-negative effect as an explanation for this observation. The results for individuals with ARAS support the, still scarce, data in the literature. © 2024 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback